BLUE OAK PHARMACEUTICAL - Key Persons

Job Titles:

• Member of the Strategic and Research Advisors Team
• Strategic Advisor

Adam Rosenberg is a Strategic Advisor and is currently a Venture Partner with RA Ventures, helping the firm launch and build innovative life sciences companies. Adam has 20+ years of industry experience and a strong track record as a CEO, director and advisor in healthcare and technology. This includes serving as CEO at Athenen Therapeutics, Link Medicine, Rodin Therapeutics, Sling Therapeutics and Teleos Therapeutics, and serving as a member of the board of directors for both public and private biotech companies.

Job Titles:

• Member of the Board of Directors
• CEO of Anji Pharmaceuticals

Brian Hubbard brings over 20 years of biopharmaceutical experience. Brian is CEO of Anji Pharmaceuticals and is responsible for its scientific vision and long-term strategy. He has directed R&D efforts at Millennium Pharmaceuticals, Novartis, and Merck in addition to academia. Brian has a proven track record of delivering therapies to the clinic and has founded several biotechnology companies. Brian received his Ph.D. in Chemistry from the University of Illinois and was a post-doctoral fellow at Harvard Medical School.

Job Titles:

• Research Advisor in Neuroscience

Dr. Bleakman is a Research Advisor in Neuroscience and a recognized neuroscientist and expert in drug discovery and development. David is currently Chief Scientific Officer of Redpin Therapeutics, a chemogenetics biotechnology company. Previously, he served in multiple leadership roles over 25 years at Eli Lilly, including most recently as Vice President and Chief Scientific Officer in neuroscience research. He is an Adjunct Professor in Neuroscience at Mount Sinai School of Medicine, NY and has co-authored over 100 peer reviewed publications, several book chapters and numerous patents. David received his Ph.D. from King's College London, University of London and completed a postdoctoral fellowship at the University of Chicago.

Job Titles:

• Member of the Strategic and Research Advisors Team
• Research Advisor in Medicinal Chemistry

Doug Burdi is a Research Advisor in Medicinal Chemistry. Doug has 25+ years of experience in both large pharma and biotech companies where he led programs that spanned a broad range of therapeutic areas, including CNS, Inflammation and Oncology. He is co-inventor on over 10 patents and patent applications and is co-author of 20 peer-reviewed publications. Doug earned a Ph.D. in Organic Chemistry from Cornell University and completed a postdoctoral fellowship at the Massachusetts Institute of Technology.

Job Titles:

• Member of the Strategic and Research Advisors Team
• Director at the Max Planck Institute of Molecular Physiology Dortmund
• Research Advisor in Medicinal Chemistry

Herbert Waldmann is a Research Advisor in Medicinal Chemistry. Herbert is currently Director at the Max Planck Institute of Molecular Physiology Dortmund and Professor of Organic Chemistry at the University of Dortmund. His research interests lie in the synthesis of signal transduction modulators and the synthesis of natural product inspired compound libraries and their biological evaluation. Herbert is a Fellow of the Royal Society of Chemistry and has been the recipient of numerous awards including the Max Bergmann Medal, the GSK Award on Chemical Biology and the Emil-Fischer-Medal. Herbert received his Ph.D. in inorganic chemistry at the University of Mainz and after a postdoctoral appointment at Harvard University, he completed his habilitation at the University of Mainz.

Job Titles:

• Member of the Board of Directors

Job Titles:

• Chief Science Officer
• Co - Founder
• Member of the Board of Directors

Kerry Spear, CSO and Co-Founder, has extensive experience in structure-based drug design and is a pioneer in the (re)emerging area of phenotypic drug discovery. Kerry is skilled in applying high-content phenotypic data and artificial intelligence methods to focus and accelerate lead generation and lead optimization processes. He brings to Blue Oak over 40 years of experience in both large pharma and biotech where he led programs that cover a broad range of drug discovery research and which have resulted in 15 NCEs advancing into clinical development in CNS as well as oncology, hematology, urology, respiratory and cardiovascular therapeutic areas. He is an Adjunct Professor of Medicinal Chemistry at Fudan University (Shanghai, China). He is co-inventor of over 60 patents and published patent applications and is co-author of 34 peer-reviewed publications. Kerry earned a Ph.D. degree in organic chemistry from the University of Wisconsin, Madison and completed a postdoctoral fellowship at the University of California, Berkeley.

Job Titles:

• Member of the Strategic and Research Advisors Team
• Strategic Advisor

Mark Corrigan is a Strategic Advisor and a recognized leader in life sciences. He has led strategic turnarounds and mergers and is unabashedly driven by a passion to create new medicines and bring them successfully to market. Mark spent a decade at Pharmacia rising to Group VP for Clinical Research and Experimental Medicine. He then joined Sepracor as CSO of Research and Development and following a successful merger with Dainippon Sumitomo, took his first CEO position at Zalicus. Subsequently, Dr. Corrigan co-founded a rare diseases company, Tremeau Pharmaceuticals and following its acquisition, he assumed the leadership of Correvio Pharma, a publicly traded, global, commercial stage company. Dr. Corrigan has extensive Board experience in research, clinical and commercial stage companies where he has served as Chairman and Executive Chairman. Mark received his MD at Univ. Virginia, residency training in psychiatry and appointment to the faculty of the University of North Carolina.

Job Titles:

• Member of the Strategic and Research Advisors Team
• Chief Medical Officer of EuMentis Therapeutics
• Research Advisor in Clinical Development

Randall Marshall is a Research Advisor in Clinical Development. Randall is currently Chief Medical Officer of EuMentis Therapeutics, and a CMO advisor for Sophrosyne and Lactocore therapeutics. Dr. Marshall brings 25+ years of experience across all aspects of clinical research, and has led programs in neurological and psychiatric disorders, in rare disease, and in hepatology and pediatric oncology. Prior to that, he held medical leadership roles of increasing responsibility at Sepracor, Sunovion, Euthymics, Neurovance, and Retrophin including co-founding ProTara Therapeutics. Randall has published more than 130 peer-reviewed publications, book chapters or books in his fields of expertise. Dr. Marshall earned his MD at Johns Hopkins University and completed his psychiatry residence and research fellowship at Columbia University, where he attained Associate Professor.

Job Titles:

• Member of the Board of Directors
• Vice President of ShangPharma Innovation

Bob Drakas is Vice President of ShangPharma Innovation with more than 20 years of experience leading therapeutic programs and cross functional teams. Bob previously served as the Executive Director of Business Development at ChemPartner Inc., a leading research organization providing services for the biopharmaceutical industry. In addition, he was part of the founding team for ShangPharma Investment Group. Earlier in his career, Bob served as senior analyst and senior research biochemist at Merck. He is board member of Blue Oak Therapeutics, Azkarra Therapeutics, ShangPharma Innovation, and board observer of Tilos Therapeutics, Mediar Therapeutics, and Evrys Bio.

Job Titles:

• Member of the Strategic and Research Advisors Team
• Research Advisor in CMC

Sandy Hurd is a Research Advisor in CMC and brings over 20 years of pharmaceutical experience. He is the current Head of CMC at Anji Pharma where he is responsible for process development and manufacturing of clinical trial materials. Sandy has rich technical experience in drug substance and drug product from supporting preclinical regulatory toxicology studies to late clinical stage and commercial development. Additionally, he has led several small molecule discovery programs at Pharmacia, Pfizer, and Lycera in antibiotics, inflammation, and auto-immune disease areas. Sandy received his Ph.D. in Chemistry from the University of Illinois and was a postdoctoral fellow at Harvard University.

Job Titles:

• CEO
• Co - Founder
• Member of the Board of Directors
• President
• Team Member

Thomas Large, CEO and Co-Founder, has broad leadership experience in biopharma spanning R&D, regulatory and new product planning functions as well as M&A, corporate integration and investor relations. He has a successful track record of partnering with large pharma, biotech, CRO, academic and government organizations. Tom is a recognized leader in the systems neurobiology of brain disorders and pioneering new paradigms for CNS drug discovery and development. At Eli Lilly, he implemented innovative research approaches in neuroscience as well as oncology and endocrine therapeutic areas. At Sepracor/Sunovion, his discovery and translational medicine group delivered multiple clinical drugs with modes-of-action distinct from existing CNS drug classes, including SEP-363856, a novel antipsychotic drug recently recognized by the FDA as a Breakthrough Therapy. His honors include President's and Alliance awards at Eli Lilly, Spirit of Innovation award at Sunovion and PhRMA representative to the White House Precision Medicine Initiative. Tom earned a Ph.D. in Neurobiology at Northwestern University, was a Howard Hughes postdoctoral scholar at UCSF and a member of the Neuroscience Dept. at Case Western Reserve Medical School. Our founders, Thomas Large and Kerry Spear, are internationally-recognized experts in translational medicine, neuropharmacology and medicinal chemistry. Both have held leadership roles at leading pharmaceutical companies like Eli Lilly and Sunovion.